News

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long ...
Finanznachrichten3d
Ascendis Pharma: New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
At Week 214, nearly all patients (98%) continued to have normal albumin-adjusted serum calcium levels and ... In the trial, TransCon PTH treatment was generally well-tolerated, with no new safety ...
MacSources3d
Advanced Detection Methods for Pass-the-Hash in Your Network
As cyber threats evolve, so do the techniques that hackers use to infiltrate networks. One of the most insidious tactics is ...